Fibrolamellar hepatocellular carcinoma
MONDO:0006210A distinctive type of liver cell carcinoma that arises in non-cirrhotic livers and is seen predominantly in young patients. The tumor cells are polygonal and deeply eosinophilic, and are embedded in a fibrous stroma. The prognosis is similar to classical hepatocellular carcinoma that arises in non-cirrhotic livers, and better than hepatocellular carcinoma that arises in cirrhotic livers.
Also known as: FHCC, FLC, fibrolamellar cancer, fibrolamellar carcinoma, fibrolamellar carcinoma of liver cells, fibrolamellar carcinoma of the liver cells, fibrolamellar hepatocarcinoma, fibrolamellar hepatocellular carcinoma
2915 clinical trials for this condition and its sub-types, 15 tagged with Fibrolamellar hepatocellular carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Fibrolamellar hepatocellular carcinoma
-
New hope for kids with liver cancer: international trial tests smarter chemo combos
Disease control OngoingThis study tests different combinations of chemotherapy drugs, along with surgery, for children and young adults with two types of liver cancer: hepatoblastoma and hepatocellular carcinoma. The goal is to see which combinations work best to stop tumor growth and improve survival.…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for young cancer patients: drug duo targets tough tumors
Disease control PausedThis study tests a new drug called DT2216 combined with the chemotherapy irinotecan in children, teens, and young adults whose solid tumors have come back or not responded to treatment. The goal is to find the safest dose and see if the combination can shrink tumors, especially i…
Phase 1/2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for rare cancers? drug combo shows promise in early trial
Disease control OngoingThis phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New Two-Drug immune attack launched against tough cancers
Disease control OngoingThis early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…
Phase 1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug combo hopes to fight tough cancers in kids and young adults
Disease control OngoingThis study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study …
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC